Endometriosis market across the 7MM to hit $2.5b by 2034

Its expansion is attributed to the introduction of several key therapies.

The endometriosis market across the seven major markets (7MM) is expected to reach $2.5b by 2034 at a compound annual growth rate of 10.3%, said GlobalData.

The sector’s expansion is primarily attributed to the introduction of several key therapies.

Moreover, the market is driven by developments in non-invasive diagnostic methods, such as the use of biomarkers.

Meanwhile, key opinion leaders identified major unmet needs in the market, including non-invasive diagnostics and disease awareness and education of medical professionals, said Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Senior Analyst at GlobalData.

These unmet needs also include more effective drugs with long-term safety and tolerability, non-hormonal therapies, and treatments that better target the disease’s underlying causes and mechanisms.

Most medical treatments for endometriosis are hormonal therapies, which have unwanted side effects, often fail to prevent the disease from returning, and prevent pregnancy.

7MM = US, France, Germany, Italy, Spain, UK, and Japan.